stockrow
Friday 6 November 2026
Export ERAS’s income statement to Excel — free account
Erasca, Inc.
ERAS Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- −4.67%
Quarter to June 2026, against a year earlier
14.34
1.07
+8.06%
Follow ERAS
Alert me
Erasca, Inc. (ERAS) Gross margin
Erasca, Inc.'s gross margin over the twelve months to 30 September 2023 was 0.00%, down 0.0 percentage points from fiscal 2022 (0.00%). That is below the Biotechnology industry median of 68.5% and below the Healthcare sector median of 54.5%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2023 | 0.00% | 0.00 |
| Jun 2023 | 0.00% | 0.00 |
| Mar 2023 | 0.00% | 0.00 |
| Dec 2022 | 0.00% | 0.00 |
| 10 more quarters | Free account |
Gross margin against peers
| Company | Gross margin |
|---|---|
| CRSP CRISPR Therapeutics AG compare | 100.0% |
| DNTH Dianthus Therapeutics, Inc. compare | 100.0% |
| TVTX Travere Therapeutics, Inc. compare | 98.5% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 56.6% |
| COGT Cogent Biosciences, Inc. compare | 0.00% |
| ERAS Erasca, Inc. | 0.00% |
| DFTX Definium Therapeutics, Inc. compare | 0.00% |
| EWTX Edgewise Therapeutics, Inc. compare | 0.00% |
| MANE Veradermics Incorporated compare | — |
| Biotechnology industry median | 68.5% |
| Healthcare sector median | 54.5% |
| Market median | 46.0% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue